Ngm Biopharmaceuticals Stock Price, News & Analysis

NGM Biopharmaceuticals, Inc. (NGM) announced details about its myeloid checkpoint inhibitor portfolio at the AACR Annual Meeting, focusing on three candidates: NGM707, NGM831, and NGM438. These candidates aim to disrupt immune suppression in tumors by targeting receptors like ILT3 and LAIR1. NGM707 is currently in a Phase 1/2 trial, while NGM831 and NGM438 are set to enter clinical trials soon. Initial data for NGM707 is expected in the second half of 2022, promising advancements in cancer treatment.

NGM Biopharmaceuticals (NGM) has initiated a Phase 1/1b trial for NGM831, an ILT3 antagonist antibody, targeting advanced solid tumors. This trial aims to enroll up to 80 patients to evaluate safety and efficacy, including its use with KEYTRUDA® (pembrolizumab). NGM831 is part of NGM's broader myeloid reprogramming portfolio, which includes NGM707 and NGM438, emphasizing innovative strategies to enhance anti-tumor immunity. NGM aims to have all three programs in clinical stages by mid-2022, with plans for robust biomarker strategies to optimize patient selection.

NGM Biopharmaceuticals (NGM), a biotech company, will host the first of its four-part Explorer Series virtual R&D events on March 30, 2022. From 11:00 am to 12:15 pm ET, the event will showcase NGM's productive discovery engine, featuring presentations from CEO David Woodhouse and CSO Jin-Long Chen. The series will introduce a preclinical program and subsequent sessions will cover ongoing therapeutic candidates: NGM707, NGM831, NGM438, and NGM621. Live webcasts will be available on NGM's website, with replays archived for a year.

NGM Biopharmaceuticals (NGM) announced that its research on myeloid reprogramming and checkpoint inhibition programs will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022. Key presentations will include NGM707, currently in a Phase 1/2 trial, focusing on immune suppression reversal. Additionally, preclinical findings for NGM831 and NGM438, both set to enter Phase 1 trials in 2022, will be highlighted. These programs aim to enhance immune responses in tumors, showcasing NGM’s innovative drug discovery capabilities.

NGM Bio reported significant advancements in its clinical pipeline during Q4 2021, including obtaining Fast Track designation for NGM621 targeting geographic atrophy due to age-related macular degeneration. The company completed enrollment in the Phase 2b ALPINE 4 trial for aldafermin, with results expected in H1 2023. Financially, NGM Bio reported a net loss of $27.2 million for Q4 and $120.3 million for 2021, but saw a cash balance increase to $366.3 million, sufficient to fund operations into H1 2024.

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals (NGM) announces CEO David J. Woodhouse will participate in the Cowen 42nd Annual Health Care Conference on March 7, at 10:30 am ET. The presentation will focus on the company's oncology portfolio and provide a comprehensive business update. Interested parties can watch a live webcast on NGM's website, which will be available for replay for 30 days post-event. NGM is dedicated to developing transformative therapies targeting cancer, retinal diseases, and metabolic disorders.

NGM Biopharmaceuticals, Inc. (NGM) announced that the FDA has granted Fast Track designation to its monoclonal antibody candidate, NGM621, designed to inhibit complement C3 for treating geographic atrophy caused by age-related macular degeneration. This designation is pivotal as it accentuates the urgent medical need for effective therapies in this area. NGM621 is currently being evaluated in the Phase 2 CATALINA study, with topline data anticipated in Q4 2022. GA affects approximately one million patients in the U.S., and there are no existing FDA-approved treatments.

NGM Biopharmaceuticals (NGM) announced a presentation by CEO David J. Woodhouse, Ph.D., at two upcoming investor conferences. The B. Riley Virtual Annual Oncology Investor Conference will take place on January 27, 2022, at 2:30 PM ET, followed by the SVB Leerink’s 11th Annual Global Healthcare Conference on February 18, 2022, at 1:40 PM ET. Live webcasts will be accessible via NGM's website, with replay available for 30 days post-event. NGM focuses on developing transformative therapeutics for cancer, retinal diseases, and liver/metabolic diseases.

NGM Biopharmaceuticals (NGM) has outlined its strategic priorities for 2022 following a transformative 2021. The company boasts a pipeline of seven programs, with four in Phase 2 trials. Key anticipated milestones for 2022 include: topline data from the Phase 2 CATALINA trial of NGM621 in Q4 2022, Phase 1a data from NGM707 in H2 2022, and the initiation of Phase 1 trials for NGM831 and NGM438. The company also highlights a renegotiated collaboration with Merck, regaining worldwide rights to oncology programs while focusing on innovative therapies for retinal and metabolic diseases.